Cleveland Research downgraded AmerisourceBergen Corp. (NYSE:ABC) to Neutral in a report released today.
- Updated: October 10, 2016
Yesterday AmerisourceBergen Corp. (NYSE:ABC) traded 0.33% higher at $79.78. ABC’s 50-day average is $84.55 and its 200-day moving average is $83.05. The last stock price is down -4.09% relative to the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 736,523 shares of ABC traded hands, down from an avg. volume of 2,014,370
Cleveland Research has downgraded AmerisourceBergen Corp. (NYSE:ABC) to Neutral in a report released on 10/10/2016.
See Chart Below
AmerisourceBergen Corp. has a 52 week low of $73.31 and a 52 week high of $105.81 with a P/E ratio of 10.74 AmerisourceBergen Corp.’s market capitalization is currently $0.
In addition to Cleveland Research reporting its stock price target, a total of 15 brokers have issued a research note on the company. The average stock price target is $85.40 with 4 brokers rating the stock a strong buy, 2 brokers rating the stock a buy, 12 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.
Brief Synopsis On AmerisourceBergen Corp. (NYSE:ABC)
AmerisourceBergen Corporation is a pharmaceutical sourcing and distribution services company. The Company operates through two segments: Pharmaceutical Distribution and Other. The Company also provides data and other services to its manufacturing customers. The Company provides services to healthcare providers, and pharmaceutical and biotech manufacturers. The Company provides pharmacy services to certain specialty drug patients. Additionally, the Company offers healthcare providers and pharmaceutical manufacturers with services, including reimbursement and pharmaceutical consulting services, logistics services, inventory management, pharmacy automation and pharmacy management. The Company has a distribution facility network totaling approximately 30 distribution facilities in the United States.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.